Cambridge-based biopharmaceutical firm, Agios Pharmaceuticals, Inc. is focused on the innovative discovery and advancement of cellular metabolism medicines. The company's product portfolio includes PYRUKYND (mitapivat), a ground-breaking activator of wild-type and mutant pyruvate kinase (PK) enzymes, which holds great potential for the treatment of hemolytic anemias. Additionally, AG-946, a PK activator has been developed to treat lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was founded in 2007 and has since been dedicated to advancing scientific breakthroughs within the field of biopharmaceuticals.
Agios Pharmaceuticals's ticker is AGIO
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 201-500 employees working at Agios Pharmaceuticals
It is agios.com
Agios Pharmaceuticals is in the Healthcare sector
Agios Pharmaceuticals is in the Biotechnology industry
The following five companies are Agios Pharmaceuticals's industry peers: